69 patents
Page 3 of 4
Utility
ANTI-CD19 Therapy In Combination with Lenalidomide for the Treatment of Leukemia or Lymphoma
6 May 21
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and lenalidomide for use in the treatment of hematological cancer patients.
Sumeet Ambarkhane, Johannes Weirather
Filed: 30 Oct 20
Utility
Anti-tumor Combination Therapy Comprising ANTI-CD19 Antibody and Gamma Delta T-cells
6 May 21
The present disclosure is directed to a combination therapy comprising an anti-CD19 antibody or antibody fragment thereof and gamma delta T-cells (γδ T-cells) for use in the treatment of leukemia or lymphoma.
Jan Endell, Rainer Boxhammer, Dominik Pretscher
Filed: 30 Oct 20
Utility
Rodent combinatorial antibody libraries
16 Feb 21
The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries.
Josef Prassler, David Ott, Stefanie Thiel, Yvonne Stark, Ute Keck, Thomas Pietzonka, Hilmar Ebersbach
Filed: 10 Mar 17
Utility
Treatment for rheumatoid arthritis
9 Feb 21
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis.
Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
Filed: 26 Jan 18
Utility
ANTI-WT1/HLA-SPECIFIC Antibodies
28 Jan 21
The present invention relates to antibodies or fragments thereof binding to human WT1/HLA.
Andrea MAHR, Toni WEINSCHENK, Dominik MAURER, Claudia WAGNER, Klaus Felix HARTLEPP, Alexandra KRAUS
Filed: 13 Oct 20
Utility
Peptide Libraries
23 Dec 20
The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
Katja Siegers, Jan Van Den Brulle
Filed: 7 Sep 20
Utility
Humanized Antibodies for CD3
2 Dec 20
The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells.
Thomas TILLER, Steffen RUNZ, Julia NEUGEBAUER, Andreas BÜLTMANN
Filed: 12 Aug 18
Utility
Anti-WT1/HLA-specific antibodies
16 Nov 20
The present invention relates to antibodies or fragments thereof binding to human WT1/HLA.
Andrea Mahr, Toni Weinschenk, Dominik Maurer, Claudia Wagner, Klaus Felix Hartlepp, Alexandra Kraus
Filed: 6 Oct 16
Utility
Combinations and Uses Thereof
11 Nov 20
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
Filed: 2 Apr 20
Utility
Combinations and Uses Thereof
11 Nov 20
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
Filed: 2 Apr 20
Utility
Peptide libraries
2 Nov 20
The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
Katja Siegers, Jan Van Den Brulle
Filed: 29 Apr 15
Utility
Complex-specific Antibodies and Antibody Fragments and Its Use
28 Oct 20
The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen.
Stefan HAERTLE, Christian FRISCH, Achim KNAPPIK
Filed: 9 Jul 20
Utility
Antagonists of IL17C for the treatment of inflammatory disorders
26 Oct 20
The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.
Andreas Bültmann, Robert Mühlbacher, Teresa Garcia, Reginald Christophe Xavier Brys, Luc Nelles, Katja Conrath
Filed: 7 Nov 18
Utility
Complex-specific antibodies and antibody fragments and its use
14 Sep 20
The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen.
Stefan Haertle, Christian Frisch, Achim Knappik
Filed: 18 Dec 17
Utility
Polypeptide Library
22 Jul 20
The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement.
Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
Filed: 7 Apr 20
Utility
Canine Antibody Libraries
15 Jul 20
The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries.
Thomas Tiller, Markus Waldhuber, Ralf Strohner, Kathrin Ladetzki-Baehs, Josef Prassler
Filed: 20 Jun 18
Utility
Antibodies for IL-17C
8 Jul 20
The present invention provides antibodies or antibody fragments binding to human IL-17C.
Jan Dominik HAAS, Jürgen KLATTIG, Nick Ernest René VANDEGHINSTE
Filed: 17 Mar 20
Utility
Combination of an ANTI-CD19 Antibody and a Bruton's Tyrosine Kinase Inhibitor and Uses Thereof
1 Jul 20
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jan ENDELL, Rainer BOXHAMMER, Mark WINDERLICH
Filed: 1 Mar 20
Utility
Polypeptide library
18 May 20
The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement.
Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
Filed: 2 Mar 17
Utility
Collection and methods for its use
11 May 20
The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties.
Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
Filed: 2 Mar 17